

Original Article

Genotyping and prevalence of *Chlamydia trachomatis* infection among women in Belém, Pará, northern Brazil

Danielle Murici Brasiliense¹, Bárbara do Nascimento Borges², Wallax Augusto Silva Ferreira²

¹ Instituto Evandro Chagas, Laboratório de Infecções Respiratórias de Origem Bacteriana, Ananindeua, Pará, Brasil

² Universidade Federal do Pará, Instituto de Ciências Biológicas, Belém, Pará, Brasil

Abstract

Introduction: Genital *Chlamydia trachomatis* infection is one of the most prevalent sexually transmitted diseases in women, and undetected cases of the disease are highly associated with long-term complications. Despite the high prevalence of infections in Brazil, very little is known about the distribution of *C. trachomatis* genovars. In this study, we determined the prevalence and genotypes of *C. trachomatis* in women treated at a public hospital in the Brazilian city of Belém, the capital of the state of Pará.

Methodology: A total of 154 women were tested for chlamydial infection by PCR using specific primers for the *C. trachomatis* cryptic plasmid. Genotyping of positive samples was performed by sequencing the *ompA* gene and conducting further phylogenetic analysis.

Results: Out of the 154 samples, 17 were found to be positive using *C. trachomatis* cryptic plasmid PCR. The overall prevalence of *C. trachomatis* infection was 11%, with the highest prevalence observed in women between 16 and 20 years of age. Five genotypes were found to be associated with endocervical infection. Genotype F was most frequently found (37.5%), followed by genotypes J (25%), E (25%), I (6.25%), and D (6.25%).

Conclusions: This study emphasizes the relevance of *C. trachomatis* infection in the young female population of the Brazilian Amazon region. It also demonstrates the diversity of genotypes involved in genital infection in this population.

Key words: *C. trachomatis*; genotyping; *ompA* gene.

J Infect Dev Ctries 2016; 10(2):134-137. doi:10.3855/jidc.6474

(Received 23 december 2014 – Accepted 25 May 2015)

Copyright © 2016 Brasiliense *et al.* This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Chlamydia trachomatis (CT) is an important human pathogen that causes various diseases and syndromes, including urogenital infection, trachoma and lymphogranuloma venereum, depending on the serovar involved [1]. As an agent of urogenital infection, *C. trachomatis* is the most prevalent bacterial sexually transmitted disease (STD), with estimated 92 million new cases annually worldwide [2]. Approximately 50% of men and 70% of women infected individuals are asymptomatic, making it difficult to diagnose and treat. When the infection remains untreated, complications such as pelvic inflammatory disease may occur, leading to severe sequelae like ectopic pregnancy and infertility [3,4].

Currently, 19 serovars and related variants (A, B/Ba, C, D/Da, E, F, G/Ga, H, I/Ia, J, K, L1, L2, L2a and L3) of *C. trachomatis* have been identified by using polyclonal and monoclonal antibodies against the major outer membrane protein (MOMP) [5,6]. Serovars A, B and C have usually been associated with trachoma,

whereas D through K have tended to correlate with urogenital infections. Serovars L1 through L3 are commonly associated with lymphogranuloma venereum [7].

Typing of *C. trachomatis* strains remains an important goal in the field of epidemiology, as do clinical and basic research on *C. trachomatis* infections. The temporal and geographical distribution of strains throughout the world has significant implications for our understanding of the epidemiology of this infectious agent and for vaccine development [5]. Moreover, typing can be an important tool to reveal transmission pathways and associations with different tissue tropisms and pathogenicity [8].

The traditional immunotyping methods are currently being replaced by genotyping methods, such as restriction fragment length polymorphism (RFLP) or DNA sequence analyses of the major outer membrane protein (MOMP) gene *ompA* (1) [5,9]. The availability of the whole genome sequence for *C. trachomatis* has led to the development of several new genotyping

systems, such as multilocus sequence typing (MLST) and multilocus variable number tandem repeat analyses (MLVA), with a higher discriminating capacity [10-12]. However, these approaches have been used within the framework of the current *ompA*-based *C. trachomatis* classification system, as there is not yet a standardized nomenclature or classification system based on these novel typing methods [8].

In Brazil, screening for *C. trachomatis* is not routinely available, and it is not mandatory to notify patients that have it. However, isolated studies carried out in this country have shown infection rates ranging from 6% to 31% among women [13,14]. The large range of reported rates reflects discrepancies in both methods used and populations evaluated [15]. Despite a high prevalence of *C. trachomatis* infection in Brazil, very little is known about the distribution and diversity of genotypes involved in genital infection.

In this study, we determined the prevalence and the genotypes of *C. trachomatis* infection in endocervical specimens from 154 women treated in a public hospital in the city of Belém (Pará), the second-largest capital in the Brazilian Amazon region.

Methodology

Clinical specimens and processing

Endocervical samples were obtained from 154 women attending Fundação Santa Casa de Misericórdia do Pará, a public hospital in the city of Belém, Pará, Brazil, between July 2012 and February 2013. The samples were obtained from recipients of three gynecological services offered by the hospital: STD screening, family planning and prenatal care. The ethical clearance for this study was granted by the IEC (CAAE: 02394512.3.0000.0019), on June 18, 2012. All women were informed and gave their written consent to participate in the study, and completed a clinical and epidemiological questionnaire. The specimens were collected with Dracon-tipped swabs or brush during routine pelvic examinations, and were subsequently placed into sterile collection tubes containing 3 ml of specimen transport medium (DIGENE). After being vigorously vortexed within the collection tubes, the swabs were removed. For pregnant women, only

cervical swabs were obtained. The samples were sent to the Molecular Biology Lab at the Evandro Chagas Institute, and stored at -20° C to await further analysis.

Screening of C. trachomatis

The endocervical samples were submitted to DNA extraction using the PureLink Genomic DNA kit (Invitrogen, Carlsbad, USA) as the manufacturer directs. To verify the efficacy of DNA extraction and the presence of PCR inhibitors, the samples were first screened using PCR specific primers for the human β -globin gene. In order to detect *C. trachomatis* DNA in the samples, a 241 base pair (bp) fragment of the genetically conserved cryptic plasmid of *C. trachomatis* was amplified using PCR [16], and *C. trachomatis* serovar L2 DNA was used as a positive control. The amplified products were visualized on a 1% agarose gel stained with SYBR Safe DNA gel stain (Invitrogen, CA). The results have been confirmed by using Hybrid Capture HC II CT-ID DNA Kit v 2.0 (DIGENE, Gaithersburg, Maryland, USA).

C. trachomatis genotyping

C. trachomatis PCR-positive samples were selected for genotyping by amplifying a 990 pb fragment of the *ompA* gene according to a nested-PCR methodology (Table 1) described elsewhere [17].

The *ompA* fragments obtained were purified using the QIA Quick PCR Purification Kit (Qiagen, Santa Clarita, CA, USA) and bidirectionally sequenced with the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, California, USA) using two inner primers (MOMP87 and RVS1059) and a 3130 Genetic Analyzer (Applied Biosystems, Foster City, California, USA).

Genotyping was performed based on a BLAST similarity search, and a phylogenetic tree analysis was generated to illustrate the evolutionary relationships between clinical isolates and reference strains. Using version 7.0 of the software program BioEdit, each sequence obtained was aligned with an analogous sequence from reference strains. The strains were derived from a GenBank database: (Gen bank accession number M58938, AF063208, M17343, X62918,

Table 1. Primer sequences used for *C. trachomatis* plasmid PCR and *ompA* gene PCR.

| Primer | Target | Reference | Strand | Sequence (5'-3') |
|--------|------------------|---------------------|-----------------|----------------------------|
| KL1 | Cryptic plasmid | Mahony et al., 1995 | sense | TCC GGA GCG AGT TACG AAG A |
| KL2 | | | antisense | AAT CAA TGC CCG GGA TTG GT |
| P1 | | | Outer sense | ATGAAAAAACTCTTGAAATCG |
| OMP 2 | <i>ompA</i> gene | Lysen et al., 2004 | Outer antisense | CTCAACTGTAAGTGCATTT |
| MOMP87 | | | Inner sense | TGAACCAAGCCTTATGATCGACGGA |
| RVS | | | Inner antisense | TCTTCGAYTTTtagGTTtagATTGA |

Genotyping Analysis

All 17 positive clinical samples for the cryptic plasmid PCR were subjected to a nested PCR for *ompA* gene amplification. The 16 samples that were successfully amplified generated a fragment of approximately 900 bp and contained all four variable domains of the *ompA* gene.

Sequence analysis of the *ompA* gene revealed that the F genotype was the most prevalent (n = 6; 37.5%), followed by E (n = 4; 25%), J (n = 4; 25%), I (n = 1; 6.25%) and D (n = 1; 6.25%). The phylogenetic analysis produced a tree that grouped the analyzed samples into five clades. Bootstrap values ranging from 86% to 100%, confirmed the identification of the five different genotypes of *Chlamydia trachomatis* in the sample studied (Figure 1).

ompA sequences obtained in our sample showed high similarity values, ranging from 99.76 to 100% when compared to those from the literature. Genotype F was highly conserved, showing 100% similarity between the sample sequences and the reference sequences, whereas genotype sequences D, E, J and I displayed either one or two nucleotide substitutions when compared to the reference sequences (Table 4). In all, nine nucleotide substitutions were observed, eight of which resulted in amino-acid replacement.

Both patient age and clinical signs and symptoms (lower abdominal pain, abnormal vaginal discharge, ectopia and cervicitis) were analyzed for possible

associations with particular *C. trachomatis* genovars, but no statistically significant associations were found.

Discussion

Studies performed in several countries show that *C. trachomatis* is the main bacterial agent of sexually transmitted disease worldwide. Variable rates of infection prevalence have been found, depending on which populations were studied and which diagnostic methods were used. Though the tracking of *C. trachomatis* is not mandatory in Brazil, several studies of prevalence have been performed in different regions of the country, with rates that have varied from 6% to 31% [13,14]. In the Amazon region, these studies are scarcer. Data mainly from female patients at an STD clinic in the city of Manaus indicated a *C. trachomatis* prevalence of 13% [19]. There are, however, no data about the genotypes that were involved in these infections.

In the present study, the prevalence of *C. trachomatis* and its genotypes was analyzed in a sampling of women from Belém, Pará, the second-largest capital in the Brazilian Amazon region. The global prevalence of chlamydial infection (11%) was similar to that found in other studies performed in Brazil under similar conditions, reflecting a national reality [20]. In 2008, Jalil *et al.* performed a wide-ranging, multicentric study in the capitals of six Brazilian states. In a population of approximately 3,000 pregnant

Table 4. Nucleotide changes found in *ompA* gene of *C. trachomatis* compared to reference sequences^a.

| Sample Identification | GenBank accession no. | Genotype | Similarity (%) | Nucleotide Change | Position ^b | Amino acid change |
|-----------------------|-----------------------|----------|----------------|-------------------|-----------------------|-------------------|
| CTPA 27 | KP269164 | F | 100.00 | - | - | - |
| CTPA 50 | KP269165 | F | 100.00 | - | - | - |
| CTPA 93 | KP269166 | F | 100.00 | - | - | - |
| CTPA 131 | KP269167 | F | 100.00 | - | - | - |
| CTPA 134 | KP269168 | F | 100.00 | - | - | - |
| CTPA 152 | KP269169 | F | 100.00 | - | - | - |
| CTPA 67 | KP269170 | E | 99.88 | G to A | 997 | A to T |
| CTPA 71 | KP269171 | E | 99.76 | A to G | 194 | Y to C |
| | | | | C to T | 1034 | S to F |
| CTPA 94 | KP269172 | E | 100.00 | - | - | - |
| CTPA 154 | KP269173 | E | 100.00 | - | - | - |
| CTPA 58 | KP269174 | J | 100.00 | - | - | - |
| CTPA 73 | KP269176 | J | 99.76 | T to G | 625 | C to G |
| | | | | A to G | 746 | E to G |
| CTPA 79 | KP269177 | J | 100.00 | - | - | - |
| CTPA 90 | KP269178 | J | 98.88 | G to A | 272 | S to N |
| CTPA 149 | KP269179 | D | 99.77 | G to A | 1013 | A to T |
| CTPA 69 | KP269175 | I | 99.76 | A to G | 526 | I to V |
| | | | | G to A | 1050 | Silent (L) |

^a The following reference strains were used for comparison with sequences obtained in this study: F/ICCal3 (X52080), E/Bour (X52557), J/UW36 (AF063202), D/IC-Cal8 (X62920) and Ia/IU-4168 (AF063201); ^b Position refer to reference sequences of each genotype and are not homologous between serotypes.

women, a *C. trachomatis* prevalence of 13.4% was observed [21].

In accordance with the findings of other studies, our results also showed an association between *C. trachomatis* and patient age, with the prevalence among women under 20 amounting to 20.4%. This rate, one of the highest ever described in Brazil, confirms youthful age as an important risk factor for *C. trachomatis* infection [19].

Although a large body of work demonstrates the high prevalence of CT infection in the Brazilian population, only two studies describe the distribution of urogenital *C. trachomatis* genotypes in the midwestern and southeastern regions of the country [15,22]. To our knowledge, this is the first study to describe the genotypic diversity of *C. trachomatis* associated with genital infection within a population residing in the northern of the country. Five different genotypes were identified in endocervical samples, with F, E and J appearing most frequently. The D genotype was detected in only one case.

The first study undertaken for genotyping of *C. trachomatis* in Brazil analyzed 12 sequences of the *ompA* gene in women treated at an STD clinic in the midwestern city of Minas Gerais. It found four genotypes. At 33.3% each, E and D were the most frequently detected, followed by F and K, which each showed a frequency of 16.7% [15]. A broader study by Machado *et al.* (2011) genotyped 163 positive *C. trachomatis* samples from men and women in two regions of Brazil: the midwestern city of Goiania and the southeastern city of Vitoria. In this study, nine distinct genotypes were encountered, the five most common being E (39.3%), F (16.6%), D (15.9%), I (8.6) and J (7.4%) [22]. In both studies, genotypes E, D and F were identified most frequently in samples from subjects with urogenital infections of *C. trachomatis*, respectively comprising 83.3% and 71.8%, of the genotypes found. These results accord with the findings of studies in other countries (such as Argentina, Costa Rica, Taiwan, Iran and Hungary), in which the same three genotypes were found to appear most frequently in urogenital cases of *C. trachomatis* [6,7,23]. In the present study, genotype F was the most frequent, followed by genotypes D and J. These findings revealed differences between the genotypic distribution of urogenital *C. trachomatis* in women from the Amazon region and that of women elsewhere in Brazil and the world. However, since the sample size is limited, more studies are warranted to better understand the distribution of *C. trachomatis* genotypes in this population.

Conclusions

The high prevalence of chlamydial infection, especially among young women, reinforces the importance of public STD-prevention policies for the aforementioned age group. More studies are necessary to better understand the epidemiology and distribution of *C. trachomatis* genotypes in women from the Amazon region.

Acknowledgements

The authors would like to thank Fundação Santa Casa de Misericórdia do Pará for the collection of samples and Instituto Evandro Chagas/Secretaria de Vigilância em Saúde/Ministério da Saúde, for the financial support.

References

1. Manavi K (2006) A review on infection with *Chlamydia trachomatis*. Best Pract Res Clin Obstet Gynaecol 20: 941-951.
2. Centers for Disease Control and Prevention (2006) Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 55: 1-94.
3. Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM, Cohen MS, Harris KM, Udry JR (2004) Prevalence of chlamydial and gonococcal infections among young adults. JAMA 291: 2229-2236.
4. Quint K, Porras C, Safaeian M, Gonzalez P, Hildesheim A, Quint W, Doorn LJ, Silva S, Melchers W, Schiffman M, Rodriguez AC, Wacholder S, Freer E, Cortes B, Herrero R (2007) Evaluation of a novel PCR-based assay for detection and identification of *Chlamydia trachomatis* serovars in cervical specimens. J Clin Microbiol 45: 3986-3991.
5. Banea CI, Kubota K, Brown TM, Kilmarx PH, Bhullar V, Yanpaisarn S, Chaisilwattana P, Siriwasin W, Black CM (2001) Typing of *Chlamydia trachomatis* strains from urine samples by amplification and sequencing the major outer membrane protein gene (*omp1*). Sex Transm Inf 77: 419-422.
6. Hsu MC, Tsai PY, Chen KT, Li LH, Chiang CC, Tsai JJ, Ke LY, Chen HY, Li SY (2006) Genotyping of *Chlamydia trachomatis* from clinical specimens in Taiwan. J Med Microbiol 55: 301-308.
7. Beni BT, Motamedi H, Ardakani MR (2010) Genotyping of the prevalent *Chlamydia trachomatis* strains involved in cervical infections in women in Ahvaz, Iran. J Med Microbiol 59: 1023-1028.
8. Pedersen LN, Herrmann B, Møller JK (2009) Typing *Chlamydia trachomatis*: from egg yolk to nanotechnology. FEMS Immunol Med Microbiol 55: 120-130.
9. Ruettinger A, Feige J, Slickers P, Schubert E, Morré SA, Pannekoek Y, Herrmann B, Vries HJC, Ehrlich R, Sachse K (2011) Genotyping of *Chlamydia trachomatis* strains from culture and clinical samples using an *ompA*-based DNA microarray assay. Mol Cell Probes 25: 19-27.
10. Bom RJM, Christerson L, Loeff MFS, Coutinho RA, Herrmann B, Bruisten SM (2011) Evaluation of high-resolution typing methods for *Chlamydia trachomatis* in samples from heterosexual couples. J Clin Microbiol 49: 2844-2853.

11. Klint M, Fuxelius HH, Goldkuhl RR, Skarin H, Rutemark C, Andersson SGE, Persson K, Herrmann B (2007) High-resolution genotyping of *Chlamydia trachomatis* strains by multilocus sequence analysis. *J Clin Microbiol* 45: 1410-1414.
12. Pedersen LN, Pødenphantand L, Møller JK (2008) Highly discriminative genotyping of *Chlamydia trachomatis* using *omp1* and a set of variable number tandem repeats. *Clin Microbiol Infect* 14: 644-652.
13. Machado MSC, Silva BFBC, Gomes ILC, Santana IU, Grassi MFR (2012) Prevalence of cervical *Chlamydia trachomatis* infection in sexually active adolescents from Salvador. Brazil. *Braz J Infect Dis* 16: 188-191.
14. Pantoja M, Campos EA, Pitta DR, Gabiatti JE, Bahamondes MV, Fernandes AMS (2012) Prevalência de infecção por *Chlamydia trachomatis* em mulheres candidatas à fertilização in vitro em serviço público de referência do Estado de São Paulo. *Rev Bras Ginecol Obstet* 34: 425-431.
15. Lima HE, Oliveira MB, Valente BG, Afonso DAF, Darocha WD, Souza MCM, Alvim TC, Barbosa-Stancioli EF, Noronha FSM (2007) Genotyping of *Chlamydia trachomatis* from endocervical specimens in Brazil. *Sex Transm Dis* 34: 709-717.
16. Mahony JB, Luinstra KE, Tyndall M, Sellors JW, krepel J, Chernesky M (1995) Multiplex PCR for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in genitourinary specimens. *J Clin Microbiol* 33: 3049-3053.
17. Lysen M, Osterlund A, Rubin CJ, Persson T, Persson I, Herrmann B (2004) Characterization of *ompA* genotypes by sequence analysis of DNA from all detected cases of *Chlamydia trachomatis* infections during 1 Year of contact tracing in a Swedish county. *J Clin Microbiol* 42: 1641-1647.
18. Ayres M, Ayres-Jr M, Ayres DL, Santos AS (2007) *BioEstat* 5.0: Aplicações estatísticas nas áreas das ciências bio-médicas. Sociedade Civil de Mamirauá. Brasil.
19. Benzaken AS, Sales DN, Junior JILP, Pedrosa VL, Garcia EG (2010) Prevalence of chlamydia and gonococcal infection in women assisted in the STI clinic of Alfredo da Matta Foundation, Manaus, Amazon. *J bras Doenças Sex Transm* 22: 129-134.
20. Garcês AX, Martinez AMB, Gonçalves CV, Germano FN, Barra MFM, Vieira VC (2013) Prevalence of *Chlamydia trachomatis* and risk factors associated with infection detected in endocervical sample. *Rev Bras Ginecol Obstet* 35: 379-383.
21. Jalil EM, Pinto VM, Benzaken AS, Ribeiro D, Oliveira EC, Garcia EG, Moherdau F, Barbosa MJ (2008) Prevalence of *Chlamydia* and *Neisseria gonorrhoeae* infections in pregnant women in six Brazilian cities. *Rev Bras Ginecol Obstet* 30: 614-619.
22. Machado ACS, Bandea CI, Alves MFC, Joseph K, Igietseme J, Miranda AE, Guimaraes EMB, Turchi MD, Black CM (2011) Distribution of *Chlamydia trachomatis* genovars among youths and adults in Brazil. *J Med Microbiol* 60: 472-476.
23. Petrovay F, Balla E, Nemeth I, Gonczol É (2009) Genotyping of *Chlamydia trachomatis* from the endocervical specimens of high-risk women in Hungary. *J Med Microbiol* 58: 760-764.

Corresponding author

Danielle Murici Brasiliense, Msc.
Laboratório de Infecções Respiratórias de Origem Bacteriana,
Seção de Bacteriologia e Micologia, Instituto Evandro Chagas. BR
316 Km 07, Ananindeua, Pará, Brazil.
Phone: +559132142116
Email: daniellemurici@iec.pa.gov.br

Conflict of interests: No conflict of interests is declared.